Search

Your search keyword '"Kimby, Eva"' showing total 799 results

Search Constraints

Start Over You searched for: Author "Kimby, Eva" Remove constraint Author: "Kimby, Eva"
799 results on '"Kimby, Eva"'

Search Results

1. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma

2. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials

4. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

7. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma

8. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

11. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

13. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

14. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

18. Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

19. Supplementary Tables S1-S2 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

20. Data from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

21. Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

22. Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab

23. Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

24. Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden

26. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

27. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

28. Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

32. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

36. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

37. Survival by first-line treatment type and timing of progression among follicular lymphoma patients: A national population-based study in Sweden

38. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

40. Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data.

43. Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

44. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

50. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Catalog

Books, media, physical & digital resources